Universal Health Realty Income Trust (UHT) Key Metrics
UHT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $530.2M
- Enterprise value
- $929.4M
- P/E (TTM)
- 27.4 10-yr median 33.0
- Forward P/E
- 38.8
- PEG ratio
- 0.63
- Price / sales
- 5.2 10-yr median 10.4
- Price / book
- 3.8 10-yr median 3.9
- EV / EBITDA
- 13.6 10-yr median 17.3
- Dividend yield
- 7.86% $3.00 a year
- Beta
- 0.85
UHT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsUHT valuation Price multiples at each fiscal year-end price.
UHT returns How much profit the business earns on the capital it uses.
UHT per-share figures Results divided by the shares outstanding at year-end.
UHT financial health Debt, liquidity and how easily interest is covered.
UHT efficiency & capital use Working capital cycle and where the cash goes.
UHT valuation history
UHT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
UHT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
UHT cash returned to shareholders
UHT price vs earnings per share
UHT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $543.6M | $514.9M | $597.5M | $658.4M | $819.4M | $884.7M | $1.61B | $842.1M | $1.02B | $883.4M |
| Enterprise value | $923.0M | $887.0M | $959.7M | $1.29B | $1.14B | $1.18B | $1.89B | $1.10B | $1.28B | $1.20B |
| P/E ratio | 30.9 | 26.8 | 38.8 | 31.2 | 7.5 | 45.5 | 85.1 | 34.8 | 22.4 | 51.3 |
| Price / sales | 5.5 | 5.2 | 6.3 | 7.3 | 9.7 | 11.3 | 20.9 | 11.0 | 14.1 | 13.2 |
| Price / book | 3.6 | 2.9 | 3.0 | 2.9 | 3.5 | 5.6 | 8.9 | 4.2 | 4.9 | 4.6 |
| Price / free cash flow | 11.1 | 11.0 | 13.7 | 19.8 | 23.6 | 21.1 | 43.0 | 21.7 | 27.7 | — |
| Price / operating cash flow | 11.1 | 11.0 | 13.7 | 14.1 | 17.2 | 20.0 | 37.8 | 19.6 | 22.2 | 21.7 |
| EV / sales | 9.3 | 9.0 | 10.0 | 14.3 | 13.5 | 15.2 | 24.5 | 14.4 | 17.6 | 17.8 |
| EV / EBITDA | 13.7 | 12.6 | 14.7 | 22.2 | 7.8 | 22.3 | 34.3 | 18.7 | 15.8 | 24.1 |
| EV / free cash flow | 18.8 | 18.9 | 22.1 | 38.9 | 32.7 | 28.2 | 50.3 | 28.3 | 34.5 | — |
| Earnings yield | 3.2% | 3.7% | 2.6% | 3.2% | 13.3% | 2.2% | 1.2% | 2.9% | 4.5% | 1.9% |
| Free cash flow yield | 9.0% | 9.1% | 7.3% | 5.0% | 4.2% | 4.7% | 2.3% | 4.6% | 3.6% | −2.2% |
| Dividend yield | 7.5% | 7.8% | 6.7% | 6.0% | 4.7% | 4.3% | 2.3% | 4.4% | 3.5% | 4.0% |
| Shareholder yield (dividends + buybacks) | 7.5% | 7.9% | 6.7% | 6.0% | 4.7% | 4.3% | 2.3% | 4.4% | 3.5% | 4.0% |
| Share price at fiscal year-end | $39.21 | $37.21 | $43.25 | $47.73 | $59.47 | $64.27 | $117.36 | $61.37 | $75.11 | $65.59 |
| Per share | ||||||||||
| Revenue per share | $7.15 | $7.15 | $6.92 | $6.57 | $6.11 | $5.67 | $5.61 | $5.55 | $5.31 | $4.98 |
| Earnings per share | $1.27 | $1.39 | $1.11 | $1.53 | $7.92 | $1.41 | $1.38 | $1.76 | $3.35 | $1.28 |
| Operating cash flow per share | $3.54 | $3.39 | $3.15 | $3.39 | $3.46 | $3.21 | $3.10 | $3.13 | $3.38 | $3.02 |
| Free cash flow per share | $3.54 | $3.39 | $3.15 | $2.41 | $2.52 | $3.05 | $2.73 | $2.83 | $2.71 | −$1.46 |
| Cash per share | $0.48 | $0.51 | $0.59 | $0.55 | $1.63 | $0.42 | $0.44 | $0.37 | $0.25 | $0.29 |
| Book value per share | $10.99 | $12.97 | $14.55 | $16.61 | $17.08 | $11.55 | $13.22 | $14.47 | $15.45 | $14.20 |
| Tangible book value per share | $10.58 | $12.44 | $13.89 | $15.92 | $16.35 | $10.70 | $12.16 | $13.21 | $13.95 | $12.43 |
| Dividends per share | $2.96 | $2.92 | $2.88 | $2.84 | $2.80 | $2.76 | $2.72 | $2.68 | $2.65 | $2.61 |
| Capex per share | $0.64 | $0.66 | $0.55 | $0.99 | $0.94 | $0.16 | $0.37 | $0.30 | $0.66 | $4.48 |
| Debt per share | $27.84 | $27.40 | $26.81 | $46.46 | $24.69 | $22.09 | $20.55 | $19.04 | $18.82 | $23.44 |
| Shares outstanding | 13.9M | 13.8M | 13.8M | 13.8M | 13.8M | 13.8M | 13.8M | 13.7M | 13.6M | 13.5M |
| Change in shares outstanding | +0.2% | +0.2% | +0.1% | +0.1% | +0.1% | +0.1% | +0.2% | +0.7% | +1.2% | +1.3% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 10.6% | 10.1% | 7.2% | 9.1% | 55.4% | 11.4% | 10.0% | 11.8% | 22.7% | 8.9% |
| Return on invested capital (ROIC) | 5.1% | 5.2% | 4.4% | 2.2% | 5.2% | 2.8% | 2.8% | 2.9% | 2.5% | 2.3% |
| Return on assets (ROA) | 3.1% | 3.3% | 2.6% | 3.5% | 20.0% | 4.0% | 3.9% | 5.0% | 9.0% | 3.5% |
| Return on tangible assets | 3.1% | 3.4% | 2.6% | 3.5% | 18.6% | 4.0% | 4.0% | 5.2% | 9.7% | 3.4% |
| Free cash flow margin | 49.5% | 47.4% | 45.5% | 36.6% | 41.3% | 53.8% | 48.7% | 51.0% | 51.1% | −29.3% |
| Income quality (OCF / net income) | 2.79 | 2.44 | 2.82 | 2.22 | 0.44 | 2.27 | 2.25 | 1.77 | 1.01 | 2.37 |
| Financial health | ||||||||||
| Total debt | $386.0M | $379.2M | $370.4M | $640.9M | $340.3M | $304.0M | $282.6M | $261.3M | $256.4M | $315.7M |
| Cash & short-term investments | $6.7M | $7.1M | $8.2M | $7.6M | $22.5M | $5.7M | $6.1M | $5.0M | $3.4M | $3.9M |
| Net debt | $379.3M | $372.1M | $362.2M | $633.3M | $317.8M | $298.3M | $276.5M | $256.2M | $253.0M | $311.8M |
| Debt / equity | 2.53 | 2.11 | 1.84 | 2.80 | 1.45 | 1.91 | 1.56 | 1.32 | 1.22 | 1.65 |
| Debt / assets | 0.68 | 0.65 | 0.62 | 1.05 | 0.57 | 0.62 | 0.58 | 0.54 | 0.52 | 0.60 |
| Net debt / EBITDA | 5.61 | 5.29 | 5.56 | 10.87 | 2.19 | 5.62 | 5.01 | 4.37 | 3.13 | 6.29 |
| Current ratio | 15.19 | 0.29 | 0.31 | 0.34 | 0.41 | 0.06 | 0.07 | 0.07 | 0.06 | 0.05 |
| Quick ratio | 15.19 | 0.29 | 0.33 | 0.38 | 0.41 | 0.06 | 0.07 | 2.39 | 2.59 | 2.51 |
| Interest coverage | 1.6 | 1.5 | 1.4 | 2.9 | 3.3 | 3.1 | 2.4 | 2.8 | 2.4 | 2.4 |
| Working capital | $18.7M | −$255.0M | −$234.8M | −$206.3M | −$167.7M | −$239.9M | −$209.5M | −$193.4M | −$181.3M | −$202.4M |
| Invested capital | $531.7M | $551.6M | $563.1M | $862.4M | $553.1M | $457.3M | $458.3M | $454.9M | $463.6M | $503.1M |
| Tangible asset value | $146.7M | $172.2M | $191.8M | $219.7M | $225.4M | $147.3M | $167.2M | $181.2M | $190.0M | $167.5M |
| Net current asset value | −$392.5M | −$296.3M | −$289.6M | −$273.4M | −$246.4M | −$318.6M | −$290.3M | −$269.9M | −$267.0M | −$321.9M |
| Graham number | $17.72 | $20.14 | $19.10 | $23.91 | $55.18 | $19.16 | $20.25 | $23.96 | $34.12 | $20.21 |
| Graham net-net per share | −$28.55 | −$23.18 | −$23.00 | −$22.02 | −$19.59 | −$23.34 | −$21.31 | −$37.48 | −$37.74 | −$43.53 |
| Capital allocation | ||||||||||
| Dividends paid | $41.0M | $40.4M | $39.8M | $39.2M | $38.5M | $38.0M | $37.4M | $36.8M | $36.1M | $35.1M |
| Share buybacks (net) | $0 | $131,000 | $0 | $0 | $0 | $267,000 | $221,000 | $0 | $0 | $0 |
| Dividend payout ratio | 233.0% | 210.0% | 258.2% | 185.7% | 35.3% | 195.3% | 197.3% | 152.2% | 79.0% | 204.1% |
| Dividends + buybacks / free cash flow | 83.6% | 86.4% | 91.5% | 118.1% | 110.9% | 91.2% | 100.2% | 94.7% | 97.5% | — |
| Capex / revenue | 8.9% | 9.2% | 8.0% | 15.0% | 15.4% | 2.9% | 6.6% | 5.3% | 12.5% | 90.0% |
| Capex / operating cash flow | 18.0% | 19.3% | 17.5% | 29.1% | 27.2% | 5.1% | 12.0% | 9.4% | 19.7% | 148.3% |
| Capex / depreciation | 0.31 | 0.33 | 0.27 | 0.52 | 0.48 | 0.09 | 0.20 | 0.16 | 0.36 | 2.62 |
| Stock-based compensation / revenue | 0.9% | 0.9% | 0.8% | 0.9% | 1.1% | 1.2% | 0.9% | 0.7% | 0.7% | 0.7% |
| R&D / revenue | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| SG&A / revenue | 6.4% | 6.2% | 6.3% | 6.3% | 27.8% | 5.3% | 5.2% | 5.0% | 4.9% | 4.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 204.7 | 360.4 | 372.5 | 385.9 | 227.4 | 49.8 | 49.2 | 46.2 | 42.2 | 38.1 |
| Days of inventory on hand | — | — | -661.7 | -859.3 | — | — | — | -46,692.6 | -51,773.4 | -29,349.3 |
| Days payables outstanding | — | — | — | — | 1,352.6 | 1,472.6 | 1,170.0 | 1,196.0 | 1,283.8 | 1,319.4 |
| Cash conversion cycle (days) | — | — | — | — | -1,125.3 | -1,422.8 | -23,336.5 | -47,842.4 | -53,015.0 | -30,630.6 |
| Receivables turnover | 1.78 | 1.01 | 0.98 | 0.95 | 1.61 | 7.32 | 7.42 | 7.89 | 8.66 | 9.57 |
| Payables turnover | — | — | — | — | 0.27 | 0.25 | 0.31 | 0.31 | 0.28 | 0.28 |
| Asset turnover | 0.17 | 0.17 | 0.16 | 0.15 | 0.15 | 0.16 | 0.16 | 0.16 | 0.14 | 0.14 |
| Average receivables | $55.6M | $97.8M | $97.5M | $95.8M | $52.4M | $10.7M | $10.4M | $9.7M | $8.4M | $7.0M |
| Average payables | — | — | — | — | $16.3M | $16.7M | $12.7M | $12.5M | $12.6M | $11.8M |
| Average inventory | — | — | −$9.6M | −$12.0M | — | — | −$241.9M | −$486.9M | −$507.4M | −$262.4M |
| Intangibles / total assets | 1.0% | 1.3% | 1.5% | 1.6% | 1.7% | 2.4% | 3.0% | 3.6% | 4.2% | 4.5% |
Computed from UHT's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
UHT valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Universal Health Realty Income traded at 30.9 times earnings, against a 10-year median of 33.0. Based on the latest twelve months, the trailing P/E is 27.4 and the forward P/E is 38.8. Universal Health Realty Income earned a return on equity of 10.6% and a return on invested capital of 5.1% in fiscal 2025. It ended the year with $386.0 million of debt and $6.7 million in cash and short-term investments, net debt of $379.3 million. It returned $41.0 million to shareholders: $41.0 million in dividends and $0 in share buybacks, 84% of free cash flow.
See the UHT income statement, the UHT chart for price history, or the UHT stock overview for the latest quote and news.
UHT key metrics FAQ
What is Universal Health Realty Income's P/E ratio?
Universal Health Realty Income's trailing P/E ratio is 27.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 38.8. At the end of fiscal 2025 it was 30.9, compared with a 10-year median of 33.0.
What is Universal Health Realty Income's EV/EBITDA?
Universal Health Realty Income's enterprise value was 13.7 times EBITDA at the end of fiscal 2025 (enterprise value $923.0 million, EBITDA $67.6 million); the current EV/EBITDA is 13.6.
What is Universal Health Realty Income's return on equity?
Universal Health Realty Income's return on equity (ROE) was 10.6% in fiscal 2025: net income of $17.6 million on average shareholders' equity of $166.0 million.
What is Universal Health Realty Income's ROIC?
Universal Health Realty Income's return on invested capital was 5.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Universal Health Realty Income have?
Universal Health Realty Income had total debt of $386.0 million at the end of fiscal 2025, a debt-to-equity ratio of 2.53 and $379.3 million of net debt (5.61 times EBITDA).
What is Universal Health Realty Income's dividend yield?
Universal Health Realty Income's forward dividend yield is 7.86%. Universal Health Realty Income paid $41.0 million in dividends in fiscal 2025 ($2.96 per share), a payout ratio of 233.0%.
What is Universal Health Realty Income's free cash flow yield?
Universal Health Realty Income generated $49.1 million of free cash flow in fiscal 2025, a free cash flow yield of 9.0% on its market value at year-end ($543.6 million).
What is Universal Health Realty Income's current ratio?
Universal Health Realty Income's current ratio was 15.19 at the end of fiscal 2025: current assets were 15.19 times current liabilities.